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We have created a novel method for coupling adenoviral vectors to solid microbeads in a way that does not adversely
affect the infectivity of the attached virions. This method utilizes the extremely tight interaction between the protein
streptavidin and its ligand biotin as a means of tethering viral particles to microbeads. The adenovirus–microbead conjugates
that were created functioned as fully infectious entities and possessed several functional advantages over free, unmodified
viral particles. The adenovirus–microbead conjugates possessed enhanced ability to transduce target cells in culture. For
target cells of a highly permissive nature, this increase in infectivity was modest. However for target cells of moderate to low
permissivity, the enhancement of transduction efficiency was substantial. Adenoviral vectors, previously incapable of
infecting a particular colon cancer cell line, were made fully infectious on the same cell line when delivered as solid-phase
conjugates. Additionally, solid-phase adenovirus–microbead conjugates showed highly limited diffusion in solution, allowing
for focused delivery of viral vectors only to cells that come into contact with the conjugates. When the solid phase to which
the viral particles were attached had paramagnetic properties, the location of viral infections was tightly controllable by
magnetic force through the use of strategically placed magnets. © 2002 Elsevier Science (USA)INTRODUCTION
A major obstacle in the use of viral vectors as thera-
peutic tools is the inability to control where such vectors
are targeted physiologically. Genetic and chemical mod-
ifications of viral envelopes or viral surface proteins to
contain binding reagents for particular cell types have
been very difficult, resulting in limited success (for recent
reviews, see Bilbao et al., 1998; Curiel, 1999; Raynolds
and Curiel, 1999; Cannon and Anderson, 2000; Hackett
and Crystal, 2000; Vile et al., 2000; Monahan and Sa-
mulski, 2000; Wolfe et al., 2000; Kay et al., 2001; Pon-
nazhagan et al., 2001). For cases where the desired sites
of genetic transduction are known, it has been possible
to target viral vectors simply by focused administration.
However, viral vectors administered to particular physi-
ological locations often diffuse to tissues and organ
systems distant from their original placement (Huard et
al., 1995; Wirtz et al., 1998; Fechner et al., 1999; Barbara
et al., 1999; Hackett and Crystal, 2000; Schellingerhout et
al., 2000; Gelse et al., 2001). This, combined with the fact
that viral vectors used in gene therapy protocols are
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204highly infectious and have very broad tropism, has gen-
erated genuine safety issues for gene therapy.
Creative methods to address these safety concerns
have not been forthcoming. Viral vectors with “activat-
able” infectivity are one possible method for controlling
the location and timing of viral infections. This has been
accomplished in one case by the chemical conjugation
of photocleavable infectivity inhibitors to viral vectors,
using light as the infectivity-activating agent (Pandori and
Sano, 2000; Pandori et al., 2002). While the precise con-
trol of the location of viral infections is potentially achiev-
able, the use of light at relatively short wavelengths,
needed for efficient activation of viral infectivity, limits the
application of such viral vectors to cases where the
desired locations of transduction are highly accessible.
Here, we describe a novel strategy for controlling the
delivery and location of viral infections. We have at-
tached adenoviral vectors directly and stably onto the
outer surface of microbeads. Viral vectors that are at-
tached to these microbeads were shown to possess
multiple functional enhancements over free viral vectors
in solution. They possess greater infectivity, particularly
on poorly permissive cells. They do not diffuse from the
areas in which the virus–microbead conjugates are ini-
tially placed; and they are highly manipulatable in mi-Key Words: viral vectors; adenovirus; solid surface; m
localized gene delivery.
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crobead-conjugated form. Also shown herein is the use
of paramagnetic microparticle–adenovirus conjugatesicrobe
as gene delivery vehicles whose ability to transduce
cells can be controlled spatially by the use of magnetic
force.
RESULTS
We have investigated the possibility of using solid
microbeads as delivery devices for adenoviral vectors.
We hypothesized that, by using the microbeads as virus
carriers, the diffusion of such viral particles could be
limited, forcing them to infect only those cells or tissue
that come in direct contact with the virus–microbead
complexes. An essential requirement for this scheme is
that such viral vectors retain biological activity (infectiv-
ity) while attached to the surfaces of microbeads. We
decided to utilize the biotin–(strept)avidin interaction as a
means of tethering viral particles to the surfaces of
microbeads. Avidin and streptavidin are proteins that
exhibit extremely high binding affinities for their ligand
biotin (Kd  10
14–1015 M) (Green, 1970, 1990; Wilchek
and Bayer, 1999). Earlier work performed in our labora-
tory revealed that chemical, covalent conjugation of bi-
otin moieties (biotinylation) to the outer surfaces of ad-
enoviral vectors can be performed with a very limited
effect on the viral infectivity. Hence, such biotinylated
viral particles could be stably attached to the surfaces of
microbeads that are coated with avidin or streptavidin. A
wide variety of microbeads are available that possess
avidin or streptavidin covalently attached to their outer
surface. In this work, we chose to utilize streptavidin-
coated silica microbeads (Bangs Labs, Fisher, IN). These
silica microbeads have a density (specific gravity) of 1.95
g/ml, approximately twice that of water, hence strongly
limiting their diffusion in solution. Streptavidin-coated
microbeads possess a high-binding capacity for biotin-
ylated macromolecules, therefore allowing a strong pos-
sibility that biotinylated viral particles could be immobi-
lized stably and tightly on their surface.
To ensure attachment of functional adenoviral vectors
to the surfaces of streptavidin-coated microbeads, we
determined conditions that allow for biotinylation of ad-
enoviral particles with minimal disturbance of their infec-
tivity. We used sulfo-NHS-LC-biotin (Pierce Chemical,
Rockford, IL) as the biotinylation reagent, as it is water-
soluble, is easy to use, and possesses a long spacer
chain that allows for greater accessibility of the biotin
moiety by streptavidin on the microbead surfaces. Addi-
tionally, the ability of this biotinylation reagent to react
specifically with primary amino groups via its N-hydroxy-
succinimidyl (NHS) group should lend itself well to the
modification of adenoviral surfaces, which consist al-
most entirely of protein. By testing a range of concentra-
tions of sulfo-NHS-LC-biotin, we found that biotinylation
of adenoviral vectors (Ad5.CMV-lacZ, which carries the
transducable lacZ gene) can be achieved with no distur-
bance of viral infectivity at a treatment concentration of
15 g/ml, in phosphate-buffered saline (PBS) (pH 7.6)
(Fig. 1). At this concentration, adenoviral vectors retained
100% of their original infectivity. Adenoviral vectors,
treated with sulfo-NHS-LC-biotin, were also mixed with
excess Neutralite avidin (a neutralized, deglycosylated
form of avidin; Southern Biotechnology Associates, Bir-
mingham, AL) to determine the effect of the conjugation
of avidin to the surface of the viral particles on viral
infectivity. For viruses that had been treated with sulfo-
NHS-LC-biotin, the addition of Neutralite avidin had a
negative effect on viral infectivity. The strength of this
negative effect correlated with the concentration of sulfo-
NHS-LC-biotin used during biotinylation of viral vectors
(Fig. 1). This indicates that the surfaces of the adenoviral
particles were indeed biotinylated and that biotin moi-
eties on the viral outer surface were accessible by avidin
molecules. In addition, adenoviral vectors, treated with
15 g/ml sulfo-NHS-LC-biotin, were completely remov-
able from solution (capturable) by using an excess
amount of streptavidin-coated microbeads (data not
shown). This result confirms the biotinylation of viral
particles on the viral outer surface and the accessibility
of biotin moieties to avidin and streptavidin.
We next attached the biotinylated adenoviral vectors to
the surfaces of streptavidin-coated silica microbeads to
determine if these viral vectors retained their ability to
infect cells while immobilized on a solid support. We
investigated two sizes of microbeads, 2.2 and 0.58 m in
FIG. 1. Infectivity analysis of adenoviral vectors treated with sulfo-
NHS-LC-biotin. Adenoviral vectors were treated with varying concen-
trations (0–100 g/ml) of sulfo-NHS-LC-biotin for 2 h on ice in the dark,
followed by the addition of excess glycine to absorb unreacted sulfo-
NHS-LC-biotin. Treated viral vectors were diluted 100-fold in PBS and
placed on monolayers of D-17P4 cells. After 48 h of exposure to viral
vectors, cells were stained for the lacZ expression using X-gal as the
substrate (solid bars). Diluted viral vectors were also mixed with ex-
cess Neutralite avidin, and the mixtures were titrated on D-17P4 cells
in the same manner as above (hatched bars). Each datum shown is the
average number of infected cells per microscopic field (2.27 mm2) and
is representative of two independent experiments.
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diameter, to determine if the diameter of the microbeads
affects the ability of viral particles to function. Adenoviral
vectors were biotinylated with sulfo-NHS-LC-biotin, as
described above, and washed by repeated ultrafiltration
to remove non-virion-associated biotinylation reagent.
Biotinylated viral vectors were combined with either 2.2-
or 0.58-m-diameter streptavidin-coated silica micro-
beads at varying ratios of viral particle to microbead.
Analysis of the supernatants of these mixtures after cen-
trifugation revealed no infectivity, indicating that all of the
viral particles had been bound to the surface of strep-
tavidin-coated microbeads. The resulting adenovirus–
microbead conjugates were washed by repeated centrif-
ugation and resuspension in fresh PBS. Adenovirus–
microbead conjugates were then placed over both
D-17P4 and C6 cells to evaluate their ability to transduce
these cells. D-17P4 cells were chosen because of their
high permissivity to adenoviral infection, while C6 cells
have demonstratively lower permissivity to such infec-
tion. Adenovirus–microbead conjugates were compared
to free, unmodified adenoviral vectors for the ability to
transduce target cells in culture. As shown in Table 1,
adenovirus–microbead conjugates showed ability to in-
fect both D-17P4 and C6 cells. Interestingly, when the
efficiency of infection is evaluated in the terms of how
many viral particles are required to establish an infec-
tious unit, adenovirus–microbead conjugates were more
infectious than unmodified adenoviral vectors present
free in solution. For D-17P4 cells, this increase in infec-
tion efficiency appears to be modest (up to approxi-
mately threefold). However for the lesser permissive C6
cell line, this increase in infection efficiency was dra-
matic, as approximately 20-fold fewer viral particles were
required when adenoviral vectors were delivered by mi-
crobeads, as compared to the same viral vectors used
free in solution. As the ratio of viral particle to microbead
was increased, the infection efficiency was not markedly
affected, indicating that the placement of multiple viral
particles per microbead might be unnecessary for max-
imal transduction capability.
Not surprisingly, when the microbeads carrying ad-
enoviral particles are viewed as infectious entities, the
infectivity of the microbeads increased notably as the
ratio of viral particle to microbead increased. At the
highest ratios of viral particle to microbead tested, the
infectivity of adenovirus–microbead conjugates reached
the point where each microbead can lead to the guar-
anteed infection of one cell. Certain conditions allowed
for even fewer than one microbead to be capable of
infecting a target cell (30 or 120 viral particles per mi-
crobead for D-17P4; Table 1). This result is derived from
the fact that the target cells were rapidly dividing
throughout the infection process. When a dividing cell (or
a cell primed for division) was infected, it resulted in two
infected cells, leading to an overestimation of the num-
ber of infection events.
TABLE 1
Infectivity of Adenovirus–Microbead Conjugates on an Engineered Dog Osteosarcoma Cell Line, D-17P4, and a Rat Glioma Cell Line, C6,
Compared to Free, Unmodified Adenoviral Vectors
Cell line
Microbead diameter
(m)
Ratio of viral particle
to microbead Viral particles/infectious unit Microbeads/infectious unit
D-17P4 2.2 3 24 1.6 8.3 0.7
D-17P4 2.2 30 26 0.65 0.88 0
D-17P4 2.2 120 48 3.5 0.40 0
D-17P4 0.58 0.6 31 8 25 12
D-17P4 0.58 6 36 3 4 2
D-17P4 0.58 24 42 11 1.3 0
D-17P4 Free virus — 61 22 —
C6 2.2 3 95 14 32 4.5
C6 2.2 30 191 76 6 2.6
C6 2.2 120 209 20 1.7 0.2
C6 0.58 0.6 77 26 127 42
C6 0.58 6 80 29 13 5
C6 0.58 24 121 13 5 0.5
C6 Free virus — 1577 506 —
Note. The data shown are the average of three independent experiments with the standard deviation.
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Having evaluated the capability of adenovirus–mi-
crobead conjugates to mediate infection of target cells
with high to moderate permissivity, we investigated
whether the placement of adenoviral vectors on mi-
crobeads might allow for the infection of cells that are
nonpermissive to adenoviral infection. Based both on
previous studies and on our own findings, we chose to
evaluate the ability of adenovirus–microbead conjugates
to infect COLO 205 cells, a human colon adenocarci-
noma cell line. COLO 205 cells are markedly nonpermis-
sive to adenoviral infection, presumably due to the pres-
ence of a very limited number of the receptor for adeno-
virus (coxsackie-adenovirus receptor) (Fechner et al.,
2000). We compared the ability of biotinylated adenoviral
vectors, bound to 0.58-m-diameter streptavidin-coated
microbeads at a ratio of approximately 30 viral particles
per microbead, to infect COLO 205 cells to that of free,
unmodified viral vectors. An equal number of viral parti-
cles, either in microbead-associated or in free form, was
applied to COLO 205 cells to directly compare the effi-
ciency of infection. As shown in Fig. 2, free adenoviral
vectors showed very little ability to transduce COLO 205
cells (lower than 8  104 infectious units per ml), in
agreement with previous studies (Fechner et al., 2000). In
contrast, adenoviral vectors that were bound to strep-
tavidin-coated silica microbeads showed marked infec-
tion of these cells, possessing a titer of at least 3  106
infectious units per ml when used at the same virus
concentration as free adenoviral vectors. These data
indicate that adenoviral vectors gain substantial advan-
tages over free viral vectors with regard to the ability to
infect poorly permissive cells by their placement on solid
microbeads. This might be derived from the fact that the
density of the adenovirus–microbead conjugates allows
for concentration of the viral particles onto the surface of
target cells, where their diffusion is highly limited. At this
location, the viral particles are forced into proximity of the
surfaces of target cells, where the binding of viral vectors
to their receptors might occur efficiently even in the
presence of a very limited number of the receptor due to
the close proximity of viral particles to the receptors.
We next tested the ability of adenovirus–microbead
conjugates to function as a tool to direct viral transduc-
tion to a specific location. Realizing that the density of
adenovirus–microbead conjugates would strongly limit
the diffusion of viral vectors in solution, we reasoned that
these conjugates could be used to force the localized
infection of target cells. To test this, adenovirus–mi-
crobead conjugates were made with either 2.2- or 0.58-
m-diameter streptavidin-coated microbeads at a ratio
of one or three viral particles per microbead, respec-
tively. These conjugates were then placed into culture
dishes containing monolayers of D-17P4 cells. This pro-
cess included the crafting of specific patterns in each
culture dish (the letters M and K). After 48 h, cells were
fixed and stained for the expression of the lacZ gene. As
shown in Figs. 3A and 3B, profound infection of D-17P4
cells can be seen distinctly in patterns in which the
adenovirus–microbead conjugates were initially placed.
Microscopic examination revealed that infected cells
were rarely, if ever, seen in other areas of the cell mono-
layer not exposed to layered microbeads (data not
shown). Clearly, the limited diffusion of the viral particles
when they were attached to solid microbeads allowed
for a focused, patterned transduction of cells.
Having controlled the location of viral transduction of
target cells using adenovirus–microbead conjugates, we
hypothesized that the same technique could also be
carried out using paramagnetic microparticles as virus
carriers. We reasoned that in using paramagnetic micro-
particles as virus carriers, one could control the location
of viral infections through magnetic force by the placement
of magnets in areas of desired transduction. To test this,
we combined adenoviral vectors, which had been biotin-
ylated with 15 g/ml sulfo-NHS-LC-biotin, with streptavidin-
coated paramagnetic microparticles (Promega). These
paramagnetic microparticles are not uniform in size and
FIG. 2. Infectivity of adenovirus–microbead conjugates on a human
colon adenocarcinoma cell line, COLO 205, compared to free, unmod-
ified adenoviral vectors. Adenoviral vectors were treated with 15 g/ml
sulfo-NHS-LC-biotin, washed of non-virion-associated biotinylation re-
agent by repeated ultrafiltration, and mixed with streptavidin-coated
silica microbeads (0.58-m diameter) at a ratio of 30 viral particles per
microbead. The adenovirus–microbead conjugates and free, unmodi-
fied adenoviral vectors were titrated for their infectivities on monolay-
ers of COLO 205 cells. At 48 h postexposure to viral vectors, cells were
stained for the lacZ expression using X-gal as the substrate. COLO 205
cells that were not exposed to adenoviral vectors but treated with X-gal
showed a small number of background positive (blue) cells. Each
datum shown is the average number of infected cells per microscopic
field (2.27 mm2) with the standard deviation from two independent
experiments.
207ADENOVIRUS–MICROBEAD CONJUGATES
shape, but they possess an average diameter of 1.0 m.
An equal amount of the paramagnetic microparticle–
adenovirus conjugates was placed into each of three
35-mm wells containing monolayers of D-17P4 cells.
Small (5 mm in diameter), round, rare-earth magnets had
been affixed onto the bottom of two of the wells in either
a singular dot pattern or a diagonal pattern of three dots,
prior to the application of paramagnetic microparticle–
adenovirus conjugates. In the third well, paramagnetic
microparticle–adenovirus conjugates were added, but no
magnets were affixed to it. These wells were subject to
gentle shaking at room temperature for 30 min, at which
time the magnets were removed, and cells were cultured
for 48 h. The monolayers of cells in the wells were fixed
and stained for the expression of the lacZ gene. As
shown in Fig. 3C, cells were clearly infected in a manner
specified by the presence of magnets. Well-defined
round spots showing highly infected cells were present
in wells where magnets had been affixed prior to the
administration of paramagnetic microparticle–adenovi-
rus conjugates. For the well where no magnets were
affixed, a random dispersal of infected cells is evident.
These results demonstrate that adenoviral vectors, at-
tached to paramagnetic microparticles, retain their bio-
FIG. 3. The use of microbeads or paramagnetic microparticles as adenoviral vector delivery vehicles for localized transduction of target cells. (A)
Adenoviral vectors were treated with sulfo-NHS-LC-biotin (30 g/ml), washed, and mixed with streptavidin-coated silica microbeads (2.2 m in
diameter) at a ratio of one viral particle per microbead. The resulting adenovirus–microbead conjugate suspension (100 l) was placed over a
monolayer of D-17P4 cells in the pattern of the letter “M.” At 48 h after the administration of the adenovirus–microbead conjugates, cells were stained
for the lacZ expression using X-gal as the substrate. (B) Adenoviral vectors, biotinylated as described above, were mixed with streptavidin-coated
silica microbeads (0.58 m in diameter) at a ratio of three viral particles per microbead. A suspension containing these conjugates in PBS (24 l)
was placed over monolayers of D-17P4 cells in the pattern of the letter “K” (left dish). An equal number of free, unmodified adenoviral vectors in the
same volume of PBS was also placed over a monolayer of D-17P4 cells in the pattern of the letter “K” (right dish). At 48 h after the administration of
the adenovirus–microbead conjugates, cells were stained for the lacZ expression as above. (C) Adenoviral vectors were treated with 15 g/ml
sulfo-NHS-LC-biotin and attached to the surface of streptavidin-coated paramagnetic microparticles at a ratio of approximately 600 viral particles per
magnetic microparticle). A suspension (2 l per well) containing paramagnetic microparticle–adenovirus conjugates was placed in three wells of a
six-well plate (35-mm well diameter) containing monolayers of D-17P4 cells. Small (5 mm in diameter), round, rare-earth magnets had been taped to
the bottom of two of the wells (one magnet placed in the center for the left well; three magnets placed in a diagonal pattern for the center well), prior
to the administration of adenovirus–microparticle conjugates. No magnet was affixed to the right well. The six-well plate was then placed at room
temperature with gentle shaking for 30 min, and the magnets were then removed from the plate. Cells were cultured for 48 h and then stained for
the lacZ expression as above.
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logical activity (infectivity), in a manner similar to adeno-
virus–microbead conjugates described above, and that
these conjugates can be targeted specifically to chosen
regions of target cells by using magnetic force for spa-
tially controlled transduction of cells.
DISCUSSION
We have shown that adenoviral particles can be con-
jugated stably to the surfaces of solid microbeads by
using the biotin–(strept)avidin interaction, with no result-
ing negative effects on the infectivity of the attached
virions. Such solid-phase-conjugated adenoviral vectors
have been shown to possess certain functional advan-
tages over the equivalent viruses that are free in solution.
Conjugation of adenoviruses to silica microbeads results
in the creation of viral vectors that have a density (spe-
cific gravity) nearly twice that of water, allowing for such
virus–microbead conjugates to resist the forces of diffu-
sion present in solutions. Hence, such virus–microbead
conjugates may have a role as safer gene therapeutic
agents, particularly for situations where it is highly un-
desirable for applied viral agents to spread into the blood
or surrounding tissues, leading to uncontrolled transduc-
tion of nontarget tissues. The density of such virus–
microbead conjugates can also be controlled, as
needed, by using microbeads with appropriate densities
as virus carriers.
Another distinct advantage of placing adenoviral vec-
tors on solid microbeads is a marked increase in trans-
duction efficiency for target cells. When compared to free
viral vectors, adenovirus–microbead conjugates pos-
sessed higher infectivity for a variety of cell lines. In
particular, the transduction enhancements gained by
solid-phase delivery were demonstrably greater on cells
of moderate or poor permissivity. The mechanism(s) of
enhanced transduction efficiency is yet to be deter-
mined. It seems relevant that the placement of viral
particles on the surfaces of microbeads that sink in
culture media or physiological solutions due to their high
densities would allow viral particles to be concentrated
onto the surfaces of cells. The microbeads might then
function as an anchor to hold the viral particles in close
proximity to the cell surfaces where encounters with
necessary viral receptors might occur more readily,
since the viral particles cannot lose their proximity to the
cell surface and their local concentration on the cell
surface is increased. It is possible that their enhanced
transduction efficiency might also involve endocytosis of
virus–microbead conjugates that is independent of the
binding of viral particles to the primary receptor for ad-
enovirus (coxsackie-adenovirus receptor). The endocyto-
sis of a microbead carrying multiple viral particles might
occur readily on the surface of a cell, even in the pres-
ence of very limited amounts of necessary viral recep-
tors, since microbeads are often rapidly taken up by cells
on which they are placed. In other experiments in our
laboratory, adenoviral vectors, which were placed on the
surfaces of flat microtiter wells using the same strepta-
vidin–biotin chemistry, did not exhibit infectivity enhance-
ments comparable to those of microbead-associated ad-
enoviral vectors, when target cells were placed directly
over such adenovirus-coated surfaces (D. A. Hobson,
M. W. Pandori, and T. Sano, unpublished data). These
differences suggest that the endocytosis of virus–mi-
crobead conjugates contributes, at least partly, to the
enhanced transduction efficiency seen with adenovirus–
microbead conjugates.
Successful attachment of adenoviral vectors to mi-
crobeads using the streptavidin–biotin interaction also
led us to the creation of similar conjugates using strep-
tavidin-coated paramagnetic microparticles as virus car-
riers. Adenovirus–paramagnetic microparticle conju-
gates were highly infectious, similar to adenovirus–mi-
crobead conjugates, but they were also highly
localizable by utilization of magnetic force. This offers yet
another potential method of controlling, externally, the
location of virus infections even in complex biological
systems.
The generation of virus–microbead/microparticle con-
jugates may offer other advantages not investigated in
this work. One obvious possibility is the ability to attach
viral vectors containing different genes of interest onto
the same microbeads. This might result in the creation of
microbeads that have the ability to guarantee the deliv-
ery of multiple genes to the same target cells.
MATERIALS AND METHODS
Virus production and cells
The adenoviral vector used in this study, Ad5.CMV-
lacZ (Qbiogene, Montreal, Canada), is derived from ad-
enovirus serotype 5 with the deletion of the viral E1A,
E1B, and E3 genes. The adenoviral vector carries the
bacterial lacZ gene (-galactosidase) under the control
of the human cytomegalovirus (CMV) immediate-early
promoter with a polyadenylation site. This viral vector
was produced by using 293A cells (Qbiogene), a subline
of 293 cells (human embryonal kidney cells transformed
by sheared adenovirus serotype 5 genome) and purified
by two rounds of CsCl gradient centrifugation, followed
by removal of CsCl by dialysis against 10 mM Tris–Cl pH
8.0, 2 mM MgCl2, 4% sucrose (Mittereder et al., 1996;
Nyberg-Hoffman and Aguilar-Cordova, 1999). The origi-
nal preparation at a concentration of 1.0  1013 viral
particles/ml (1.0 1012 infectious units/ml) was diluted in
PBS to 1.0  1010 viral particles/ml (1.0  109 infectious
units/ml) and stored frozen at 70°C until used.
The following three cell lines were used as targets for
infection by adenoviral vectors: D-17P4 (engineered dog
osteosarcoma cells), C6 (rat glioma cells; American Type
Culture Collection, ATCC), and COLO 205 (human colon
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adenocarcinoma cells; ATCC). D-17P4 is a derivative of
the dog osteosarcoma cell line D-17 (ATCC), which has
been stably transfected with the plasmid pPSMA2 (Car-
ter et al., 1996; Luthi-Carter et al., 1998) (a gift from Dr.
Joseph T. Coyle, McLean Hospital, Belmont, MA).
pPSMA2 carries a cDNA for the human prostate-specific
membrane antigen (PSMA) under the control of the CMV
immediate-early promoter. D-17P4 cells have been
shown to express high levels of PSMA on their surface
by fluorescence-activated cell-sorting analysis using a
monoclonal antibody against PSMA (clone Y-PSMA1; Yes
Biotech Lab, Ontario, Canada) (data not shown). D-17P4
and C6 cells were maintained in Dulbecco’s modified
Eagle’s medium (BioWhittaker) supplemented with 6%
fetal bovine serum (FBS; BioWhittaker). COLO 205 cells
were maintained in RPMI 1640 (BioWhittaker) supple-
mented with 10% FBS, 4.5 mg/ml glucose, 1.5 mg/ml
sodium bicarbonate, and 10 mM HEPES (N-2-hydroxy-
ethylpiperazine-N-2-ethane sulfonic acid).
Biotinylation of adenoviral vectors
Sulfo-NHS-LC-biotin (Pierce Chemical) was used as
the biotinylation reagent. Dilutions of a sulfo-NHS-LC-
biotin stock solution (3 mg/ml in dimethylformamide)
were added to 200 l (2.4  109 viral particles) of an
adenoviral vector solution in PBS (pH 7.6) to various final
concentrations (0–100 g/ml). The mixtures were placed
on ice, in the dark, for 2 h, and then 90 mM glycine in PBS
(pH 7.6) was added to each reaction mixture to absorb
unreacted sulfo-NHS-LC-biotin. Three rounds of ultrafil-
tration using ZM-500 centrifugal filtration units (molecu-
lar mass cutoff, 500 kDa; Millipore) with PBS (pH 7.4)
containing 0.05% Tween 20 (PBST) were used for the
removal of non-virion-associated biotinylation reagent.
The following two assays were performed for initial
assessment of the biotinylation of adenoviral vectors. In
the first assay method, biotinylated adenoviral vectors,
after the addition of 90 mM glycine, were diluted 100-fold
in PBS. Aliquots (100 l) of each reaction mixture were
mixed with 8 l Neutralite avidin (5 mg/ml; Southern
Biotechnology Associates) or PBS as a control. The re-
sulting mixtures were incubated for 30 min at room
temperature, and their infectivity was analyzed by the
following procedure. D-17P4 cells (5  104) were seeded
in wells (15.5 mm in diameter) of a 24-well plate 24 h
prior to infection. Biotinylated adenoviral vectors, with
the addition of excess Neutralite avidin or PBS, were
placed over monolayers of cells and incubated at 37°C.
At 48 h postexposure, cells were fixed with 0.5% glutar-
aldehyde and stained for -galactosidase (LacZ) activity
using 5-bromo-4-chloro-3-indolyl--D-galactopyranoside
(X-gal) as the substrate. Infected, lacZ-expressing cells
were readily identifiable by their blue cytoplasm and
were counted using a light microscope. Untreated ad-
enoviral vectors were used as controls, in which no
effect of the addition of Neutralite avidin was seen (data
not shown).
In the second assay method, biotinylated adenoviral
vectors (approximately 6  108 viral particles in 50 l)
were mixed with streptavidin-coated silica microbeads
with a diameter of 2.2 m (10 l containing approxi-
mately 9.8  107 microbeads; Bangs Labs). The mixtures
were centrifuged for 3 min at 5000 g, and the superna-
tants were analyzed for the presence of viral particles by
infectivity assays using D-17P4 cells as in the first assay
method above.
Preparation and analysis of adenovirus–microbead
conjugates
Adenoviral vectors were biotinylated with 15 g/ml
sulfo-NHS-LC biotin as described above. After the re-
moval of non-virion-associated biotinylation reagent by
ultrafiltration, biotinylated viral vectors were conjugated
to the surfaces of streptavidin-coated silica microbeads
with a diameter of either 0.58 m (5  1010 microbeads
per ml) or 2.2 m (9.8  109 microbeads per ml) (Bangs
Labs). An equal amount of biotinylated viral vectors (6 
108 viral particles in 50 l) was combined with 0.5, 2, or
20 l of a streptavidin-coated silica microbead suspen-
sion. This correlates to viral particle to microbead ratios
of 24, 6, and 0.6, respectively, for the 0.58-m-diameter
microbeads, and of 120, 30, and 3, respectively, for the
2.2-m-diameter microbeads. Analysis of the superna-
tants of these mixtures after centrifugation revealed no
infectivity, indicating that the binding capacity of the
streptavidin-coated microbeads for biotinylated adenovi-
ral vectors was not exceeded under the viral particle to
microbead ratios used. Adenovirus–microbead conju-
gates were washed with PBS (pH 7.6) supplemented with
0.5% Tween 20 (PBST) by three rounds of centrifugation
at 5000 g for 3 min at 4°C, with each spin followed by
resuspension of the conjugates in 1 ml of fresh PBST.
Finally, adenovirus–microbead conjugates were resus-
pended in PBS without Tween 20 at final microbead
concentrations of 1.25  106 microbeads/l for the 0.58-
m-diameter microbeads and 2.4  106 microbeads/l
for the 2.2-m-diameter microbeads. During these ma-
nipulations, no apparent loss of microbeads was seen by
visual inspection.
The infectivity of these adenovirus–microbead conju-
gates was determined by using either D-17P4, C6, or
COLO 205 cells as targets. Cells (5  104) were seeded
in wells (15.5 mm in diameter) of a 24-well plate 24 h
prior to infection. A suspension (1 or 5 l after appropri-
ate dilutions) containing adenovirus–microbead conju-
gates in PBS, which were fully dispersed by gentle pi-
petting, was placed over monolayers of cells (volume of
culture medium, 1.0 ml per well) and incubated at 37°C.
For control experiments, free adenoviral vectors in the
same volume of PBS were added to cells and incubated
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at 37°C. At 48 h postexposure, cells were fixed and
stained for -galactosidase (LacZ) activity by using X-gal
as the substrate, as described above.
For the analysis of localized transduction of target
cells by these conjugates, D-17P4 cells were plated in
culture dishes (1  107 cells per 150-mm-diameter dish
and 2  105 cells per 35-mm dish) 24 h prior to infection.
A suspension (100 l for the 150-mm-diameter dish and
24 l for the 35-mm-diameter dish) containing adenovi-
rus–microbead conjugates in PBS was placed over
monolayers of cells (volume of culture medium, 12 ml for
the 150-mm-diameter dish and 2 ml for the 35-mm-diam-
eter dish) in the pattern of the letter “M” or “K.” As a
control, an equal number of free adenoviral vectors in 10
l PBS was placed over cells. Cells were cultured at
37°C for 48 h and stained for the expression of the lacZ
(-galactosidase) gene using X-gal as the substrate, as
described above.
Preparation and analysis of adenovirus–paramagnetic
microparticle conjugates
Biotinylated adenoviral vectors (6  108 viral particles
in 50 l), prepared as above, were combined with a
suspension of streptavidin-coated paramagnetic micro-
particles (2 l containing approximately 1  106 para-
magnetic microparticles with an average diameter of 1.0
m; Promega). The mixtures were incubated at room
temperature for 30 min with occasional mixing by gentle
pipetting. Analysis of the supernatants (unbound frac-
tions) of these mixtures after centrifugation showed no
infectivity, indicating that all of the viral particles had
been bound to streptavidin-coated paramagnetic micro-
particles (an average of approximately 600 viral particles
per magnetic microparticle). Adenovirus–microparticle
conjugates were washed by centrifugation of the mix-
tures and subsequent resuspension of the microparticle
pellets in fresh PBST. Final adenovirus–microparticle pel-
lets were resuspended in 100 l PBST at a concentration
of approximately 1  104 paramagnetic microparticles/
l. No apparent loss of adenovirus–microparticle conju-
gates was seen by visual inspection during these pro-
cedures. The infectivity of these adenovirus–micropar-
ticle conjugates was determined by titration on D-17P4
and C6 cells using the same method as for adenovirus–
microbead conjugates as described above.
For analysis of the ability of these conjugates to be
localized by magnetic force, D-17P4 cells (2  105) were
placed in wells (35 mm in diameter) of a six-well plate
24 h prior to infection. A suspension (2 l) containing
adenovirus–microparticle conjugates in PBS was placed
over monolayers of cells (volume of culture medium per
well, 2 ml) and incubated at 37°C. For control experi-
ments, the same number of free adenoviral vectors in 2
l PBS was added to cells and incubated at 37°C. Small,
rare-earth (neodymium-iron-boron) magnets (5 mm in
diameter; 10,800 G; Tandy Corp., Fort Worth, TX) were
taped to the bottom of the wells using standard masking
tape, prior to the administration of adenovirus–micropar-
ticle conjugates. The plates were gently shaken using an
orbital shaker at room temperature for 30 min, and then
the magnets were removed from the plates. Cells were
cultured at 37°C for 48 h and stained for the expression
of the lacZ (-galactosidase) gene using X-gal as the
substrate.
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